Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches

Bibliography

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29
   PubMed Web of Science ®Google Scholar
• La vecchia C, Bosetti C, Lucchini F, et al. Cancer Mortality in Europe, 2000 – 2004, and an overview of trends since 1975. Ann Oncol 2010;21(6):1323-60
   PubMed Web of Science ®Google Scholar
• Marques RB, Dits NF, Erken-schulze S, et al. Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS One 2010;5(10):e13500
   PubMed Web of Science ®Google Scholar
• Holzbeierlein J, Lal P, Latulioppe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164(1):217-27
   PubMed Web of Science ®Google Scholar
• Mohler JL. Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol 2008;617:223-34
   PubMedGoogle Scholar
• Attard G, Reid AH, Olmos D, de Bono JS. Antitumor activity with with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 2009;69(12):4937-40
   PubMed Web of Science ®Google Scholar
• Reid AH, Attard G, Barrie E, De Bono JS. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 2008;5(11):610-20
   PubMedGoogle Scholar
• Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26(2):242-5
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T imunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22
   PubMed Web of Science ®Google Scholar
• De Bono JS, Oudard S, Ozgouroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147-54
   PubMed Web of Science ®Google Scholar
• De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1195-2005
   PubMedGoogle Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213-23
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-97
   PubMed Web of Science ®Google Scholar
• Beer TM, Smith DC, Hussain A, et al. Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium. Br J Cancer 2012;107(5):808-13
   PubMed Web of Science ®Google Scholar
• De Bono JS, Molife LR, Sonpavde G, et al. Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Ann Oncol 2012;23(5):1241-9
   PubMed Web of Science ®Google Scholar
• Hussain A, DiPaola RS, Baron AD, et al. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 2009;20(3):492-7
   PubMed Web of Science ®Google Scholar
• Nelson PS. Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol 2012;30(6):644-6
   PubMed Web of Science ®Google Scholar
• Molenaar N, Bijkerk RM, Beishuizen A, et al. Steroidogenesis in the adrenal dysfunction of critical illness: impact of etomidate. Crit Care 2012;16(4):R121
   PubMedGoogle Scholar
• Cai C, Chen S, Ng P, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 2011;71(20):6503-13
   PubMed Web of Science ®Google Scholar
• Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9(4):401-6
   PubMed Web of Science ®Google Scholar
• Sharma A, Yeow WS, Ertel A, et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 2010;120(12):4478-92
   PubMed Web of Science ®Google Scholar
• Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001;93(22):1687-97
   PubMed Web of Science ®Google Scholar
• Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33-9
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, She Y, Khokhar NZ, et al. Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events. Mol Carcinog 2004;41(3):150-63
   PubMed Web of Science ®Google Scholar
• Thompson J, Hyytinen ER, Haapala K, et al. Androgen receptor mutations in high-grade prostate cancer before hormonal therapy. Lab Invest 2003;83(12):1709-13
   PubMed Web of Science ®Google Scholar
• Steinkamp MP, O'Mahony OA, Brogley M, et al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 2009;69(10):4434-42
   PubMed Web of Science ®Google Scholar
• Simental JA, Sar M, Lane MV, et al. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 1991;266(1):510-18
   PubMed Web of Science ®Google Scholar
• Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20(13):3001-15
   PubMed Web of Science ®Google Scholar
• Richards J, Lim AC, Hay CW, et al. Interactions of abiraterone, eplerenone, and prednisone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res 2012;72(9):2176-82
   PubMed Web of Science ®Google Scholar
• Dehm SM, Regan KM, Schmidt LJ, et al. Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells. Cancer Res 2007;67(20):10067-77
   PubMed Web of Science ®Google Scholar
• Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancer treated with androgen antagonist. Cancer Res 1999;59(11):2511-15
   PubMed Web of Science ®Google Scholar
• Li Y, Hwang TH, Oseth LA, et al. AR intragenic deletions linked to androgen receptor splice variants expression and activity in models of prostate cancer progression. Oncogene 2012;31(45):4759-67
   PubMed Web of Science ®Google Scholar
• Li Y, Chan SC, Brand LJ, et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2013;73(2):483-9
   PubMed Web of Science ®Google Scholar
• Hu R, Lu C, Mostaghel EA, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 2012;72(14):3457-62
   PubMed Web of Science ®Google Scholar
• Liu G, Sprenger C, Sun S, et al. AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer. Neoplasia 2013;15(9):1009-17
   PubMed Web of Science ®Google Scholar
• Haile S, Sadar MD. Androgen receptor and its splice variants in prostate cancer. Cell Mol Life Sci 2011;68(24):3971-81
   PubMed Web of Science ®Google Scholar
• Edwards J, Bartlett JM. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor. BJU Int 2005;95(6):1320-6
   PubMedGoogle Scholar
• Rocchi P, So A, Kojima S, et al. Heat schock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004;649180:6595-602
   Google Scholar
• Rocchi P, Beraldi E, Ettinger S, et al. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 2005;65(23):11083-93
   PubMed Web of Science ®Google Scholar
• Denmeade SR, Isaacs JT. Development of prostate cance treatment: the good news. Prostate 2004;58(3):211-24
   PubMed Web of Science ®Google Scholar
• Rocchi P, Jugpal P, So A, et al. Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces via caspase-3 activation in vitro. BJU Int 2006;98(5):1082-9
   PubMed Web of Science ®Google Scholar
• Andrieu C, Taieb D, Baylot V, et al. Heat schock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells though eIF4E. Oncogene 2010;29(13):1883-96
   PubMed Web of Science ®Google Scholar
• Cai C, Wang H, Xu Y, et al. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res 2009;69(15):6027-32
   PubMed Web of Science ®Google Scholar
• Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008;8(7):497-511
   PubMed Web of Science ®Google Scholar
• Park K, Dalton JT, Narayanan R, et al. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol 2013; PMID 24297949; Epub ahead of print
   Web of Science ®Google Scholar
• Chen Y, Chi P, Rockowitz P, et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med 2013;19(8):1023-9
   PubMed Web of Science ®Google Scholar
• Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 2013; doi:10.1038/onc.2013.206
   PubMed Web of Science ®Google Scholar
• Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18(1):11-22
   PubMed Web of Science ®Google Scholar
• Gao H, Ouyang X, Banach-Petrosky WA, et al. Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1 PTEN mutant mice. Cancer Res 2006;66(16):7929-33
   PubMed Web of Science ®Google Scholar
• Jiao J, Wang S, Quiao R, et al. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 2007;67(13):6083-91
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhu J, Efferson CL, et al. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a PTEN-deficient mouse model of prostate cancer. Cancer Res 2009;69(18):7466-72
   PubMed Web of Science ®Google Scholar
• Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011;19(5):575-86
   PubMed Web of Science ®Google Scholar
• Mulholland DJ, Tran LM, Li Y, et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 2011;19(6):792-804
   PubMed Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN, et al. TOR signaling in growth and metabolism. Cell 2006;124(3):471-84
   PubMed Web of Science ®Google Scholar
• Robbins CM, Tembe WA, Baker A, et al. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res 2011;21(1):47-55
   PubMed Web of Science ®Google Scholar
• Mulholland DJ, Kobayashi N, Ruscetti M, et al. PTEN loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 2012;72(7):1878-89
   PubMed Web of Science ®Google Scholar
• Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the met receptor in prostate cancer metastasis to bone. Urology 2002;60(6):1113-17
   PubMed Web of Science ®Google Scholar
• Verras M, Lee J, Xue H, et al. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 2007;67(3):967-75
   PubMed Web of Science ®Google Scholar
• Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143(2):401-9
   PubMed Web of Science ®Google Scholar
• Gettman MT, Pacelli A, Slezak J, et al. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology 1999;54(3):479-85
   PubMed Web of Science ®Google Scholar
• Strohmeyer D, Rossing C, Bauerfeind A, et al. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 2000;45(3):216-24
   PubMed Web of Science ®Google Scholar
• Morrissey C, Dowell A, Koreckij TD, et al. Inhibition of angiopoietin-2 in LuCap 23.1 prostate cancer tumors decreases tumor growth and viability. Prostate 2010;70(16):1799-808
   PubMed Web of Science ®Google Scholar
• Huss WJ, Barrios RJ, Foster BA, et al. Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression. Prostate 2013;54(1):8-16
   Google Scholar
• Sieveking DP, Lim P, Chow RW, et al. A sex-specific role for androgens in angiogenesis. J Exp Med 2010;207(2):345-52
   PubMed Web of Science ®Google Scholar
• Huang CN, Huang SP, Pao JB, et al. Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy. Ann Oncol 2012;23(3):707-13
   PubMed Web of Science ®Google Scholar
• Bronte V, Kasic T, Gri G, et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 2005;201(8):1257-68
   PubMed Web of Science ®Google Scholar
• Gannon PO, Poisson AO, Delvoye N, et al. Characterization of the intraprostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 2009;348(1-2):9-17
   PubMed Web of Science ®Google Scholar
• Roden AC, Moser MT, Tri SD, et al. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol 2004;173(10):6098-108
   PubMed Web of Science ®Google Scholar
• Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007;12:4957-71
   PubMed Web of Science ®Google Scholar
• Troy A, Davidson P, Atkinson C, Hart D. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J Urol 1998;160(1):214-19
   PubMed Web of Science ®Google Scholar
• Ebelt K, Babaryka G, Figel AM, et al. Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate 2008;68(1):1-10
   PubMed Web of Science ®Google Scholar
• Miller AM, Lundberg K, Ozenci V, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177(10):7398-405
   PubMed Web of Science ®Google Scholar
• Yokokawa J, Cereda V, Remondo C, et al. Enhanced functionality of CD4+CD25highFoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008;14(4):1032-40
   PubMed Web of Science ®Google Scholar
• Watkins SK, Zhu Z, Riboldi E, et al. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest 2011;121(4):1361-72
   PubMed Web of Science ®Google Scholar
• Hubert P, Jacobs N, Caberg JH, et al. The cross-talk between dendritic and regulatory T cells: good or evil? J Leukoc Biol 2007;82(4):781-94
   PubMed Web of Science ®Google Scholar
• Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 2005;96(9):1241-6
   PubMed Web of Science ®Google Scholar
• Yamaoka M, Hara T, Hitaka T, et al. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol 2012;129(3-5):115-28
   PubMed Web of Science ®Google Scholar
• Dreicer R, Agus DB, MacVicar GR, et al. Safety, pharmacokinetics and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: a phase I/II, open-label study [abstract 3084]. J Clin Oncol (Proceedings of the ASCO Annual Meeting) 2010;28:15s
   PubMedGoogle Scholar
• Agus DB, Stadler WM, Shevrin DH, et al. Safety, efficacy and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): updated data from a phase I/II study [abstract 4531]. J Clin Oncol (Proceedings of the ASCO Annual Meeting) 2011;29:15s
   Google Scholar
• George DJ, Corn PG, Michaelson MD, et al. Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with non metastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): updated results of a phase II study [abstract 4549]. J Clin Oncol (Proceedings of the ASCO Annual Meeting) 2012;30:5s
   Google Scholar
• Available from: clinicaltrials.govNCT01193257, NCT01193244,NCT01707966, NCT01084655,NCT01709734, NCT01171898,NCT013117641, NCT01162395,NCT01681433, NCT01834651,NCT01605227, NCT01522443,NCT00095667, NCT00246753, NCT01234311, NCT01090765,NCT01322490, NCT01650194,NCT01634061, NCT01574937,NCT00459186, NCT01051570, NCT00574769, NCT00313599,NCT01427322, NCT01083368,NCT01553188, NCT01513733,NCT01420965, NCT01867333,NCT01688492, NCT01832870,NCT01741116
   Google Scholar
• Leibowitz AR, Joshua AM. Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol 2012;19(S3):22-31
   Google Scholar
• Handratta VD, Vasaitis TS, Nijar VC, et al.Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmakokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem 2005;48(8):2972-84
   PubMed Web of Science ®Google Scholar
• Vasaitis T, Belosay A, Schayowitz A, et al. Androgen receptor inactivation contributes to antitumor efficacy of 17alfa-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl) androsta-5,16-diene in prostate cancer. Mol Cancer Ther 2008;7(8):2348-57
   PubMed Web of Science ®Google Scholar
• Soifer HS, Souleimanian N, Wu S, et al. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J Biol Chem 2012;287(6):3777-87
   PubMed Web of Science ®Google Scholar
• Montgomery R, Eisenberger M, Rettig M, et al. Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC). J Clin Oncol (Proceedings of the ASCO Annual Meeting). 2012;30:abstract 4665
   Google Scholar
• Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012;72(6):1494-503
   PubMed Web of Science ®Google Scholar
• Rathkopf DE, Morris MJ, Fox JJ, et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol 2013;31(28):3525-30
   PubMed Web of Science ®Google Scholar
• Pinto A. Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer. Cancer Biol Ther 2013;15(2):PMID 24100689
   Google Scholar
• Fizazi K, Massard C, James N, et al. ODM-201, a new generation androgen receptor inhibitor for castration resistant prostate cancer: preclinical and phase I data. J Clin Oncol (Proceedings of the ASCO Annual Meeting) 2013;31(Suppl 6):abstract 65
   Google Scholar
• Zhang Y, Castaneda S, Dumble M, et al. Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer. Mol Cancer Ther 2011;10(12):2309-19
   PubMed Web of Science ®Google Scholar
• Bianchini D, Omlin A, Pezaro C, et al. First-in human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br J Cancer 2013;109(10):2579-86
   PubMed Web of Science ®Google Scholar
• Sadar MD. Small molecule inhibitors targeting the “Achilles heel” of androgen receptor activity. Cancer Res 2011;71(4):1208-13
   PubMed Web of Science ®Google Scholar
• Andersen RJ, Mawji NR, Wang J, et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010;17(6):535-46
   PubMed Web of Science ®Google Scholar
• Loddick SA, Ross SJ, Thomason AG, et al. AZD3514: a small molecule that modulates androgen receptor signaling and function in vivo. Mol Cancer Ther 2013;12(9):1715-27
   PubMed Web of Science ®Google Scholar
• Zoubeidi A, Gleave M. Small heat shock proteins in cancer therapy and prognosis. Int J Biochem Cell Biol 2012;44(10):1646-56
   PubMed Web of Science ®Google Scholar
• Fiset PO, Gounni S. Antisense oligonucleotides: problems with use and solutions. Rev Biol Biotech 2001;1:27-33
   Google Scholar
• Chi K, Yu EY, Ellard S, et al. A randomized phase II study of OGX-427 plus prednisone (p) vs p alone in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) [abstract 121]. J Clin Oncol (Proceedings of the ASCO Annual Meeting) 2012;30:5S
   Google Scholar
• Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis and tumor growth. Mol Cancer Ther 2011;10(12):2298-308
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29(19):2660-6
   PubMed Web of Science ®Google Scholar
• Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013;31(4):412-19
   PubMed Web of Science ®Google Scholar
• Dubrovska A, Kim S, Salamone RJ, et al. The role of PTEN/AKT/PI3K signaling in maintenance and viability of prostate cancer stem-like cell population. Proc Natl Acad Sci USA 2009;106(1):268-73
   PubMed Web of Science ®Google Scholar
• Cao C, Subhawong T, Albert JM, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 2006;66(20):10040-7
   PubMed Web of Science ®Google Scholar
• Majumder PK, Febbo PG, Bikoff R, et al. MTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10(6):594-601
   PubMed Web of Science ®Google Scholar
• Templeton AJ, Dutoit V, Cathomas R, et al.Phase II. Trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer. Eur Urol 2013;64(1):150-8
   PubMed Web of Science ®Google Scholar
• Nakabayashi M, Werner L, Courtney KD, et al. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int 2012;110(11):1729-35
   PubMed Web of Science ®Google Scholar
• Liu Y, Majumder S, McCall W, et al. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res 2005;65(8):3404-9
   PubMed Web of Science ®Google Scholar
• Liu G, Chen YH, Kolesar J, et al. Eastern Cooperative Oncology Group. Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urol Oncol 2013;31(2):211-18
   PubMed Web of Science ®Google Scholar
• Ozen M, Giri D, Ropiquet F, et al. Role of fibrobalst growth factor receptor signaling in prostate cancer cell survival. J Natl Cancer Inst 2001;93(23):1783-90
   PubMed Web of Science ®Google Scholar
• Acevedo VD, Gangula RD, Freeman KW, et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and epithelial-to-mesenchymal transition. Cancer Cell 2007;12(6):559-71
   PubMed Web of Science ®Google Scholar
• Mukherji D, Temraz S, Wehbe D, Shamseddine A. Angiogenesis and anti-angiogenic therapy in prostate cancer. Crit Rev Oncol Hematol 2013;87(2):122-31
   PubMed Web of Science ®Google Scholar
• Chi KN, Ellard SL, Hotte SJ, et al. A phase II study of sorafenib in patients with chemo-naïve castration-resistant prostate cancer. Ann Oncol 2008;19(4):746-51
   PubMed Web of Science ®Google Scholar
• Kelly WK, Halabi S, Carducci M, et al. Randomized, double blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer CALGB 90401. J Clin Oncol 2012;30(13):1534-40
   PubMed Web of Science ®Google Scholar
• Saylor PJ, Mahmood U, Kunawudhi A, et al. Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer. J Nucl Med 2012;53(11):1670-5
   PubMed Web of Science ®Google Scholar
• Dalrymple SL, Becker RE, Isaacs JT. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. Prostate 2007;67(7):790-7
   PubMed Web of Science ®Google Scholar
• Pili R, Haggman M, Stadler WM, et al. Phase II randomized, double-blind, placebo-controlled study of tasquinmod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 2011;29(30):4022-8
   PubMed Web of Science ®Google Scholar
• Rosen LS, Hurwitz HI, Wong MK, et al. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res 2012;18(17):4820-9
   PubMed Web of Science ®Google Scholar
• Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6(5):507-16
   PubMed Web of Science ®Google Scholar
• Mita AC, Takimoto CH, Mita M, et al. Phase I study of AMG386, a selective angiopoietin ½-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 2010;16(11):3044-56
   PubMed Web of Science ®Google Scholar
• Gulley J, Chen AP, Dahut W, et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 2002;53(2):109-17
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28(7):1099-105
   PubMed Web of Science ®Google Scholar
• Vergati M, Cereda V, Madan RA, et al. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol Immunother 2011;60(2):197-206
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
   PubMed Web of Science ®Google Scholar
• Fong L, Kwek SS, O'Brien S, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009;69(2):609-15
   PubMed Web of Science ®Google Scholar
• Small E, Higano C, Tchekmedyan N, et al. Randomized phase II study comparing 4 monthly doses of ipilimumab (mdx-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer [abstract 4609]. J Clin Oncol (Proceedings of the ASCO Annual Meeting) 2006;24:18s
   Google Scholar
• Cha E, Small EJ. Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer? Cancer Med 2013;2(2):243-52
   PubMed Web of Science ®Google Scholar
• Mkrtichyan M, Najjar YG, Raulfs EC, et al. Anti-PD1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol 2011;41(10):2977-86
   PubMed Web of Science ®Google Scholar
• Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011;71(18):6019-29
   PubMed Web of Science ®Google Scholar
• Ning YM, Gulley JL, Arlen PM, et al. Phase II trial of bevacizumab, thalidomide, docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28(12):2070-6
   PubMed Web of Science ®Google Scholar
• Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase I dose-escalation trial. Lancet Oncol 2012;13(5):501-8
   PubMed Web of Science ®Google Scholar
• Van den Eertwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogenic prostate cancer cell and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase I dose-escalation trial. Lancet Oncol 2012;13(5):509-17
   PubMed Web of Science ®Google Scholar